Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force Post ContentnbixRead More You might also be interested in reading Harte Hanks GAAP EPS of -$0.33, revenue of $47.13M. February 7, 2025 In Mainstream ← Previous post Next post →